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Abstract: 
Atherosclerosis is a chronic inflammatory vascular disease. As it is an inflammation process, 
many cellular and molecular events are involved at each step of the progression of 
atherosclerosis from an early fatty streak lesion to a highly dangerous rupture-prone plaque. 
Magnetic Resonance Imaging (MRI) is a well-established diagnostic tool for many kinds of 
chronic inflammation in various systems and organs, and recent improvements in spatial 
resolution and contrast strategies make it a promising technique for the characterization of 
inflammatory vessel walls. The first part of this review will briefly introduce the main cellular 
and molecular processes involved in atherosclerotic lesions; the second part will focus on the 
use of high-resolution MRI and present-generation contrast agents for plaque characterization; 
and the third part will present some recent and ongoing cellular and molecular MRI studies of 
atherosclerosis. 
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Introduction 
Magnetic Resonance Imaging (MRI) has continuously developed, enhancing image quality 
and thereby providing more information on the physio-pathological status of biological tissue. 
The unique advantages of MR for tissue characterization lie in its inherent contrast flexibility, 
combining different sequences and various contrast media. For atherosclerosis, recent 
advances in coil and acquisition chain technologies in current clinical scanners have increased 
spatial resolution, enabling carotid plaque to be imaged with a high signal-to-noise ratio in 
patients. Carotid plaque is characterized by MRI using multi-contrast acquisition with or 
without non-specific contrast agent injection. However, for the diagnosis of vulnerable 
plaque, new contrast agents dedicated to molecular imaging and in vivo biological targeting 
are required. The question that remains unresolved is the choice of biological target to achieve 
this goal. 
Histopathologically, atherosclerosis is characterized by a progressive accumulation of lipids, 
cells (smooth muscle cells, macrophages, and T-lymphocytes) and extracellular matrix in the 
arterial wall. The progression of atherosclerosis from an initial fatty streak to the complex 
advanced lesion has been described using Stary’s six-stage histological classification 1. It is 
now established that molecular and cellular inflammatory processes are involved at each step 
of the pathology 2-4. The initial events comprise disrupted endothelial homeostasis, 
characterized by four elements: adhesiveness, permeability, proliferation and thrombogenesis. 
The initial steps of inflammation are thus clearly described at the interface between blood and 
vessel wall. The multiple molecular and cellular events explaining subsequent progression are 
often viewed from the inside of the vessel wall, except for the late event when a clear rupture 
happens at the wall/blood interface, accompanied by thrombus formation. As these cellular 
and molecular processes are also found in numerous other human disorders 5-8, any new 
diagnostic technology for atherosclerosis would also have a wider impact for the molecular 
imaging of chronic inflammatory diseases. The increasing number of original articles and 
reviews demonstrates that atherosclerosis and inflammation are important new challenges for 
MRI. In the present review, after a short description of the essential biological events, we will 
focus on the potential diagnostic contribution of MRI and MRI markers at each stage of the 
atherosclerotic disease and for detecting a vulnerable lesion ahead of rupture. 
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I. Atherosclerosis: the molecular and cellular processes involved in of an inflammatory 
disease 
Blood-side events 
Activation of vascular endothelial cells and circulating blood cells together with an increased 
plasma concentration of inflammatory mediators is characteristic of ongoing inflammatory 
processes during the progression of atherosclerosis. Some circulating markers of 
inflammation (e.g., C-reactive protein (CRP), cell adhesion molecules (CAM), monocyte 
chemoattractant protein (MCP-1), tumor necrosis factor-alpha (TNFα), interleukins (IL), 
soluble CD40 ligand (sCD40L), or von Willebrand factor) are currently undergoing clinical 
trials in patients suffering from cardiovascular diseases 5-14.  
Upon activation, circulating white blood cells express adhesion glycoproteins at their surface 
(Figure 1). Activated platelets also play a key role as a link between inflammation, thrombosis 
and atherogenesis 15,16. Like leukocytes, platelets can roll on the surface of inflamed 
endothelium. This process is mediated by endothelial P-selectin  and a counter-receptor for P-
selectin 17-19. This glycoprotein is part of the GPIb-IX-V complex, which mediates platelet 
adhesion to exposed sub-endothelial von Willebrand factor at injury sites 20. Its involvement 
in platelet adhesion to both activated endothelium and exposed subendothelium makes 
GPIbα, one of the four polypeptides of the complex, an attractive model for the design of 
mimetic compounds 21. Activated endothelial cells express CAMs, which favor the 
recruitment of leukocytes into the arterial wall 22. The main receptors expressed in the 
vascular components (Figure 1) are divided into five groups 23:  
1) Integrins:  Integrins are heterodimers of α α subunits and α β subunits. The 
integrin family has subfamilies, designated as β1 through β8. The most widely 
studied subfamilies are β1 (CD29 or very late activation (VLA) members), β2 
(leukocyte integrins such as CD11a/CD18, CD11b/CD18, CD11c/CD18, and αdβ2), 
β3 (CD61 and CD51/CD61 or ανβ3 integrin or vitronectin receptor), and β7 (α4β7 
and αEβ7). A particular integrin may recognize several proteins. 
2) Immunoglobulins: The immunoglobulin superfamily includes leukocyte function 
antigen-2 (LFA-2 or CD2), leukocyte function antigen-3 (LFA-3 or CD58), 
intercellular adhesion molecules (ICAMs), vascular adhesion molecule-1 (VCAM-1), 
platelet-endothelial cell adhesion molecule-1 (PECAM-1), and mucosal addressin 
cell adhesion molecule-1 (MAdCAM-1). The binding sites are different for each of 
these cell-adhesion molecules. 
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3) Cadherins: Cadherins are major cell-cell adhesion molecules. The most 
extensively studied are N-cadherin, E-cadherin, P-cadherin, and NgCAM. One 
unique feature of the cadherin family is homophilic binding: i.e., cadherins bind 
identical cadherins on other cells. 
4) Selectins: The selectin family (CD62) includes E-selectin, P-selectin, and L-
selectin. Selectins are well-known examples of proteins interacting with saccharide 
structures. Selectins are type-1 glycoproteins that share common structural 
determinants. P-selectin (CD62P, PADGEM, GMP-140) and E-selectin (CD62E, 
ELAM-1) are inducible receptors expressed on activated endothelial cells and/or 
platelets and binding to glycoconjugates on most leukocytes 24. L-selectin (CD62L, 
previously known as MEL-14 antigen or LECAM-1) is constitutively expressed on 
circulating lymphocytes, neutrophils, monocytes and platelets, and recognizes 
specific ligands on endothelial cells. 
5) Proteoglycans: The proteoglycans encompass a large group of core proteins with 
attached sulfated glycosaminoglycans (GAG). The specificity of their interactions 
with vascular components is related to the nature and distribution of the GAG chains 
25. 
Thus, arterial wall dysfunction is modulated by interaction between blood elements 
(circulating leukocytes, platelets, and microparticles derived from platelets or damaged 
endothelial cells), circulating or local bioactive molecules, cellular and molecular arterial 
wall components and the lesion’s microenvironment (blood flow, wall shear stress, and 
thrombogenic elements). The goal is then to identify lesions at risk of acute event: i.e., 
rupture and thrombosis.  
 
Inside the wall inflammation cascade 
Precursor signs of atherogenesis are early phenotypic modulations of intimal smooth muscle 
cells and cellular activation of the vessel wall by oxidized lipids (oxLDL) and reactive oxygen 
species (ROS) (Figure 1). Endothelial cells and macrophages are mainly involved in these 
early processes (Figure 1). For later evolution, pathological examination has demonstrated 
that plaques with thin ulceration-prone fibrous caps with inflammatory characteristics are 
responsible for fatal acute thrombosis. This finding has led to the concept of vulnerable 
lesions, independently of stenosis degree and plaque volume 2,26-28.  
Macrophages and foam cells (lipid-laden macrophages originating from monocytes or from 
smooth muscle cells) are seen as the central actors in the vicious circle of the establishment 
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of atherosclerosis, but many other cells are also involved in the process. Cell recruitment 
from the blood stream is followed by migration of cells such as T cells and mast cells from 
the immune system. In the vessel wall, smooth muscle cells are activated to a proliferating 
and secretory phenotype (Figure 1). A cascade of signaling and processes such as 
activation, proliferation, angiogenesis, enzymatic reactions and apoptosis causes evolution 
to move towards the formation of a complex plaque. 
The following events are linked to atherosclerotic plaque evolution: 
- activation of an inflammatory process; 
- oxidative stress and production of reactive oxygen species (ROS); 
- modified phenotypes (activation, proliferation); 
- apoptosis; 
- angiogenesis; 
- thrombogenesis. 
These processes involve many cellular and molecular agents. The frequently cited 
inflammatory mediators or markers (both circulating and tissue-bound) are naturally 
considered as targets for diagnostic and therapeutic approaches 5,6,14,26,28-32.  
 
The presence of key players in circulating blood, at the blood/tissue interface or inside the 
vessel wall is leading to a new concept of vulnerability. Vulnerable plaques are rupture-prone 
lesions with a prothrombotic microenvironment. A vulnerable patient is a patient at risk of an 
acute vascular event, presenting a combination of local and systemic risk factors. Clinical 
biomarkers and molecular imaging of key identified targets will help guide indications and 
treatment of vulnerable plaque 2,5,9,14,28. 
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II. MRI techniques for vessel wall imaging: role of contrast agents in plaque 
characterization 
For any imaging modality, the first step is to visualize the vessel wall in vivo. This is 
technically challenging as it requires both high spatial resolution and a high signal-to-noise 
ratio with a minimal acquisition time. Historically, attempts to characterize atherosclerotic 
plaque components were made ex-vivo, to determine whether the contrast versatility of MRI 
was helpful. From these initial studies, it was found necessary to associate multiple sequences 
– i.e., T1, T2, proton density and diffusion weighted sequences – to obtain useful information 
about plaque composition (Figure 2).  
MR characteristics of plaque components 
Recent reviews have described plaque components examined by MRI in experimental and 
clinical studies. Lipid and necrotic components, fibrous tissue with a dense or loose matrix 
and extracellular lipids, fibrocellular tissue, calcification with cholesterol crystals, and fresh 
and old thrombi have been extensively explored 32-41. Calcification is unequivocally 
characterized by absence of signal on MR sequences (Figure 2), dense fibrosis by a high 
signal on T2, lipid-necrotic core by a low signal on T2 and a variable signal on T1, and fresh 
thrombus by a high signal on T1. Many studies are now focusing on characterizing the fibrous 
cap – thickness, presence of fissures or inflammation sites, as elements for the assessment of 
lesion vulnerability or instability. MR contrast agents are very useful here, to delineate the 
fibrous cap and ulcerations and enhance inflamed tissues 42-47. 
In vivo high-resolution MRI techniques in clinical and experimental settings 
In vivo techniques involve high resolution sequences with the best compromise for temporal 
resolution. Until recently, spin echo sequences were considered the most useful, despite their 
relatively long acquisition time.  
In humans, most clinical plaque imaging studies have been performed on the carotids. Carotid 
imaging in patients involves four prerequisites: 
- optimized coil for small field of view (carotid coil); 
- carefully adjusted coil and patient position, to ensure patient comfort; 
- multiple-contrast high-resolution sequences in minimal acquisition time; 
- ECG synchronization and bright and black blood acquisitions, with swallowing and 
respiratory motion under control. 
Imaging at 3 Tesla or higher magnetic fields is beneficial in terms of increased signal-to-noise 
ratio 48, but limitations such as specific absorption rate (SAR) deposition and optimal coil 
design still need to be fully explored. 
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Experimentally, high resolution is even more crucial in animal models of atherosclerosis such 
as hypercholesterolemic rabbits or genetically modified mice. In these studies, the main focus 
of research is seldom plaque component identification but rather physiopathological 
exploration by molecular targeting and bioengineering, with MRI being used in a multimodal 
exploration context 49. 
Role of clinically available contrast agents 
Plaque permeability and neovascularization is explored with MRI via conventional non-
specific contrast agents 43,46,47,50. Either a compromised low-resolution sequence for dynamic 
acquisition or a single post-contrast time point with a spatial resolution T1 sequence can be 
used. Non-specific contrast agents diffuse rapidly in the fibrous cap, enabling measurement of 
thickness and assessment of reactivity 42,44-46. In MR acquisition using T1 agents, a 
sufficiently robust T1 sequence, meeting all the requirements of in vivo acquisition (black 
blood, ECG synchronization, stable T1 weighting, exclusion of respiratory artifacts, multi-
slice 2D or 3D) remains to be obtained 51-53. The main studies using gadolinium chelates have 
dealt with vasa vasorum in the adventitia and angiogenesis. Kinetic models are then applied to 
evaluate parameters such as blood volume and permeability index 46,50. The principal 
limitations of kinetic modeling are those encountered for tumoral angiogenesis measurement: 
i.e., interstitial diffusion of non-specific contrast agents, and the non-linear relationship 
between MR signal and contrast agent concentration. The additional difficulty for kinetic 
studies in the vessel wall is to combine strong and fast T1-weighted MR acquisition, high 
spatial resolution, a reference blood curve kinetic, and blood and fat signal suppression.  
 
Two main issues are awaiting the arrival on the market of new blood pool agents 54. First, 
blood pharmacokinetics is far more appropriate for the study of plaque permeability and 
neovascularization 55 (Figure 3). Second, the capacity to shorten either tissue T1, T2 or T2* is 
extended by using macromolecular platforms or nanoparticles 28,31,56-58. The efficiency of a 
paramagnetic MR contrast agent is described by its relaxivities r1 and r2, which are the 
constants of proportionality between contrast agent concentration and change in longitudinal 
or transversal relaxation rate, expressed in s-1. mM-1 per gadolinium or iron unit. With non-
specific gadolinium contrast agent, r1 efficiency is rather low (3 to 5 s-1. mM-1) at a 1.5T 
clinical magnetic field. Moreover, commercial gadolinium complexes are composed of a 
single gadolinium entity, whereas blood pool agents may contain several tens of contrast ions. 
The ratio between r2 and r1 determines whether a contrast agent can be better used for 
contrast-enhanced T1-weighted or T2/T2*-weighted imaging. The gadolinium-based contrast 
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agents (see example in Figure 3) are generally employed as T1 agents generating positive 
contrast (bright spot), as their r2/r1 ratio is low (typically between 1.1 and 2), whereas iron 
oxide particles are more often viewed as T2* or susceptibility agents with dark spots (Figure 
4).  
Ultrasmall iron oxide particles (USPIO) have a versatile behavior, depending on their coating 
and the size of the iron crystal. They are used either as T1 agents for MR angiography 
applications or as T2/T2* agents for cell labeling purposes 31,54,59-62. When injected in the 
blood stream, iron oxide particles encounter phagocytosis by cells of the reticulo-endothelial 
system. In atherosclerosis, small or ultrasmall iron oxide particles (SPIO or USPIO) have 
been evaluated both experimentally 61-70 and clinically 71-75, as markers of activated 
monocytes/macrophages, using gradient echo sequences and the T2* effect. Intra-plaque iron 
particle deposition is visualized as susceptibility-induced signal loss 64. Contrast changes are 
related to macrophage iron uptake inside the plaque. However, the intensity of contrast 
changes depends on many critical factors: i.e., the animal model (genetically modified mice, 
Watanabe rabbits, or New Zealand rabbits with endothelial denudation and fat diet), and the 
MRI protocol (USPIO dose and characteristics, MR sequences and imaging window), as 
discussed in dedicated papers 67,76. 
Studies using iron oxide nanoparticles as markers of activated macrophages in various 
inflammatory contexts such as stroke or multiple sclerosis have shown that signal loss is a 
combination of iron particle uptake by macrophages and non-specific diffusion of 
nanoparticles as a consequence of increased permeability and neovascularization in inflamed 
tissue 77. Discriminating T1, T2 and T2* effects is then thought to help the determination of 
iron location in the extracellular space (T1 effect) and its cellular internalization (T2* effect) 
61. The combination of both should allow follow-up of iron uptake and cell trafficking after 
iron uptake. Specificity could also be improved by modified coatings or by conjugating the 
particles with specific ligands (see next section). Thus, ongoing USPIO research aims at 
improving the specificity and quantification of iron nanoparticles: 
1/ by combining T2/T2* and T1 effects on the MR signal using different MR sequences to 
improve iron location and quantification 61,77; 
2/ by developing MR sequences to generate positive signal from susceptibility effects 78,79;  
3/ by functionalizing USPIO to target the inflammatory process 28,49; 
4/ and by performing direct tracking of iron or fluorescently labeled monocytes by a 
combination of optical and MR techniques 80.  
H
AL author m
anuscript    inserm
-00162554, version 1
H
AL author m
anuscript    inserm
-00162554, version 1
III. Cellular and molecular targeting of atherosclerosis by MRI markers 
MRI markers can be designed to target either cellular players at the blood/vessel interface or 
deeper inside the vessel wall, or molecular components identified as key biomarkers (i.e., 
soluble markers circulating in blood or in the interstitium, or molecules expressed at the 
surface of activated cells). The main targets and protocols are summarized in Table 1. 
 
In a first approach, non-specific contrast agents or blood pool contrast agents with dynamic 
contrast enhancement protocols can be used to evaluate inflammatory consequences such as 
increased permeability and neovascularization 45,50,55,81,82 (Figure 3).  
 
Cellular MRI in atherosclerosis is mainly represented by monocyte/macrophage imaging. 
Macrophages were the first targeted cells to be explored by MRI for two reasons: they have a 
central role in the inflammatory process, and their MR labeling by iron oxide particles is well-
known 64,71-73. They have been characterized in various experimental animal models 
(Watanabe rabbit or New Zealand rabbit, fed with a fatty diet after endothelial injury). After 
iron oxide uptake by macrophages, a susceptibility effect and a focal signal loss is induced, 
co-located with inflammation on histopathology (Figure 4). Ongoing studies are exploring the 
influence of the pharmacokinetic behavior and surface coating of the particles (starch, 
dextran, polyethylene glycol, anionic charges, etc.) on increasing macrophage uptake and MR 
response specificity, thereby decreasing the non-specific signal from the passive diffusion of 
iron oxide 31,62,66-69. The fundamental requirements to go on to large-scale clinical trials with 
USPIOs are: first, to improve specificity and quantification of iron-induced signal changes in 
the vessel wall; second, to design standardized protocols on clinical scanners at 1.5 and 3T; 
and lastly, to document late iron particle biotransformations in inflammatory tissue and their 
consequences for longitudinal intra-plaque signal intensity monitoring 67,76. 
 
For molecular imaging, targeting can address the main events of atherosclerosis evolution: 
i.e., inflammation and angiogenesis, oxidative stress, proliferation and apoptosis and 
thrombosis (Table 1). 
 
Inflammation and angiogenesis targeting 
The main inflammation targets are cell adhesion molecules (CAM) (Figure 1). MR markers 
have been designed to target immunoglobulins, such as VCAM-1 49,83, the selectin family, 
such as E selectins 84-87 and integrins (alpha-ν beta-3) 88-90. As the expression of adhesion 
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molecules on activated endothelial cells has been extensively explored in biology and 
biochemistry, targeting specificity is generally tested on these cells. For VCAM-1, a very 
small iron oxide particle (CLIO) is used as contrast carrier, combined to a mimetic of VLA4 
(Figure 1), the main ligand of VCAM-1. A fluorochrome is added on the iron particles to 
enable dual optical and MR detection 49,83. Targeting efficiency was demonstrated by an 
extensive in vitro study 83, confirmed in vivo in mice and improved by the phage display 
technique 49,91 (Figure 5). For E-selectin, two targeting strategies have been employed, one by 
adding a monoclonal antibody fragment to the CLIO particles 84 and the second by grafting a 
mimetic of the E-selectin ligand onto a gadolinium complex 85. The specificity of the new 
markers was evaluated in vitro 84,85, ex-vivo and in vivo in animal models 86,87. In addition, a 
strategy using a mimic of a P-selectin ligand was recently evaluated in mice by our own team 
to target plaque inflammation 92.  
Alpha-ν beta-3 integrin was targeted by addition of the RGD peptide or RGD mimetic on 
either perfluorocarbon Gd platforms 89,90 or iron oxide particles 93,94. The general applications 
were neovascularization in tumors and angiogenesis 94, but the strategy was also applied to 
plaque inflammation diagnosis with the exciting new option of targeted drug delivery 88,89. 
Oxidative stress 
As vessel wall accumulation of lipids triggers oxidative stress, lipophilic or LDL particle 
markers are of particular interest for plaque imaging. One study investigated specific binding 
to LDL via the LDL receptor interaction: a lipophilic gadolinium-based agent with an 
additional fluorophore was synthesized to label LDL particles in vitro and to track labeled 
LDL in vivo 95. Other lipophilic gadolinium agents such as gadofluorine 96 or gadolinium 
micelles 82 were applied to plaque imaging in rabbits and mice, and gadolinium liposomes 81 
and functionalized HDL particles 97 to plaque imaging in mice. Gadolinium micelles have 
been successfully immunolabeled using the biotin-avidin-biotin bridge technique to target the 
macrophage scavenger receptor 98.  
Oxidative stress is also under investigation by targeting enzymes such as matrix 
metalloproteinase 99 or myeloperoxidase 100. 
Proliferation and apoptosis 
Smooth muscle cell proliferation is involved in the response to vessel wall injury (Figure 1). 
For proliferation, two options have already been tried on cell cultures, one for molecular 
imaging only and the second with addition of local drug delivery 56,101. The target was tissue 
factor, a transmembrane glycoprotein present at the surface of activated cells. It is responsible 
H
AL author m
anuscript    inserm
-00162554, version 1
H
AL author m
anuscript    inserm
-00162554, version 1
for the initial phases of thrombosis and is also involved in proliferation and angiogenesis. The 
marker was designed to target proliferating smooth muscle cells expressing tissue factor 56. 
Apoptosis is a key process in many malignant progressions, such as cancer, chronic 
inflammation and atherosclerosis. The membrane translocation of the apoptosis marker 
phosphatidylserine (PS) was targeted in two ways: the design of fluorescent CLIO particles 
with annexin V 102 and the synthesis of annexin V-conjugated gadolinium or iron liposome 
containing quantum dots for dual MRI and optical detection 103,104. 
Thrombosis 
The final process is thrombosis, which can be detected either by natural MR contrast of 
methemoglobin 34,105,106 or by specific fibrin markers 106-110. For fibrin marker validation, 
proof of concept and validation steps include imaging of fibrin labeled clots, in vitro 
experiments and in vivo administration 107,109,110. Perfluorocarbon particles enabled enhanced 
specificity by additional 19F MRI 110. 
 
Each new MR marker validation involves the following steps: 1/ establishing the relevance of 
the chosen strategy in terms of targeting and specificity of the newly synthesized compound; 
2/ MRI detection of the marker and the limit of sensitivity; 3/ co-location of the marker with 
the target, confirmed by experimentally enhanced target expression or by in vitro and in vivo 
competition protocols; and 4/  in vivo validation after a systemic injection with careful 
examination of pharmacokinetic profile and discrimination from non-specific enhancement 
(for gadolinium) or background noise (for iron particles). The first three phases are shared by 
any sensor and have been handled with optical probes in confocal microscopy. This is one 
reason for associating the gadolinium or iron marker with a fluorophore in the development of 
new MR markers. The second reason is the lack of sensitivity with MRI. For gadolinium 
contrast agents, the limit for one gadolinium unit is usually in the micromolar range. 
Sensitivity can be increased to the nanomolar or even the picomolar range by increasing the 
relaxivity per gadolinium unit (high relaxivity agents) and by formulation with a high pay-
load of gadolinium per binding molecule (macromolecules, gadolinium nanoparticles or 
gadolinium liposomes) 56. Another way is to choose a target with a large number of binding 
sites, such as fibrin 108. For iron oxide particles, the susceptibility effect is more powerful than 
the paramagnetic effect and iron particles are already loaded with multiple irons, with an in 
vitro detection limit in the nano- to pico-molar range. However, in vivo detection with iron 
oxide particles requires careful protocols, as a dark spot is more difficult to interpret than a 
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bright spot. Thus, the specificity of in vivo iron oxide imaging is MR-sequence-dependent and 
new detection strategies are still under intense investigation 78,79. 
 
Limitations to the clinical use of Gd-based and iron-based platforms for molecular imaging 
in atherosclerosis 
From the increasing amount of experimental data on atherosclerosis and targeted MR contrast 
agents, several limitations can be identified.  
First, for gadolinium-based markers, non-specific uptake due to increased inflammatory tissue 
permeability makes a dynamic follow-up from one hour to 24 hours post-injection mandatory, 
to highlight differences between non-specific and specific enhancement. The poor sensitivity 
of MRI is also an important limitation when using gadolinium agents. An optimal balance has 
to be found between the number of gadolinium unit per macromolecule (i.e., >100), the 
stability of the gadolinium complex, a high relaxivity per gadolinium unit and conserved 
macromolecule r1 relaxivity at high magnetic field. The poor sensitivity also limits the choice 
of target, which needs to have a high expression level in the lesion.  
The steric hindrance of these gadolinium platforms (nanoparticles >100nm) determines 
specific routes for biodistribution and clearance, and sets limits to extracellular targets. 
Moreover, clinical applications will be subject to safety concerns: i.e., liver uptake and Gd 
complex stability, which will have to be determined as a function of formulation and 
biodistribution. For clinical applications, cheap and easy chemistry will also be a major 
concern for synthesis scale-up. 
The limitations with iron oxide particles lie mainly in their negative effect on the signal and in 
the lack of quantification. On gradient echo, small signal loss at short TE is difficult to 
discriminate from artifacts: a long TE gives larger susceptibility effects but with poor image 
quality and location. In animal compared to human studies, larger USPIO doses are injected 
(typically, 45 µmol Fe/kg in humans versus 200 to 1,000 µmol Fe/kg in animals). The 
interspecies variability of USPIOs’ blood half life and pharmacokinetics, which are also dose 
dependent (partly by saturation of the reticulo-endothelial system), makes it difficult to 
extrapolate experimental results to clinical findings. By testing different USPIO preparations, 
it has been shown that prolonged blood residence facilitates penetration into deep 
compartments such as atherosclerotic lesions; but a long delay between injection and the 
imaging window is then a major issue for clinical application. The time after injection to 
allow the signal from blood to decrease as well as the non-specific distribution by 
permeability gives an acquisition window that may be delayed by as long as 5-7 days after 
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USPIO administration. Lastly, for clinical applications, long-term follow-up of iron 
nanoparticle biotransformation, and of the fate of iron-labeled cells, will be required to fully 
understand their behavior in inflammatory tissue. 
 
The ultimate goal for clinical diagnosis is to characterize vulnerable plaque by molecular 
imaging. Plaque rupture is a major cause of atherothrombosis; unfortunately there is no 
animal model for plaque rupture with consequences such as sudden death, brain or myocardial 
infarction. Plaque rupture has been reported in the innominate artery of ApoE KO mice, but 
the interval between thrombus formation and thrombolysis is much shorter than in humans, 
making it very difficult to observe 111-114; also, the thrombus is very small in mice compared 
to humans. Defining vulnerable plaque in animal models has to take account of these kinetic 
factors, and plaque vulnerability biomarkers also need to adapt to such interspecies 
differences. In the literature, the ApoE KO mouse is the most common animal model of 
atherosclerosis, often using a western diet for up to 6 months to study inflammation and the 
key processes involved in plaque vulnerability. Another animal model is the Watanabe rabbit, 
which also has to be fed a high-fat diet to increase plaque inflammation. For vessel wall 
inflammation in the rabbit, the alternative is a surgically induced endothelial lesion, together 
with a high fat diet. Depending on the animal model used, very different results are observed, 
as shown with USPIOs 63-66,68-70,115.  
 
Conclusion 
The present review deals with the interplay between the complex vascular biology involved in 
plaque formation, inflammation and atherothrombosis and the potential role of MR contrast 
agents in this interplay. We focused on inflammation and adhesion molecules to illustrate 
their high potential for molecular imaging with MRI. They can be injected directly, both to 
target elements in the blood stream, as adhesion molecules are present both at the surface of 
immune cells and platelets, and to characterize the vessel wall, as they are highly expressed 
on activated endothelium and plaque components. Moreover, a growing body of evidence 
shows their importance in advanced lesions as a link between inflammation and immune 
response on the one hand and thrombosis on the other. The triggering sequence leading to 
plaque rupture is still a matter of debate. In humans, the definition of vulnerable plaque is 
moving towards a more integrated vision of the vulnerable patient. In animal models, plaque 
rupture is rarely seen, and moreover shows interspecies differences that have to be taken into 
account in defining plaque vulnerability. Bringing molecular imaging and vascular biology 
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together will provide new information on dynamic processes, such as inflammation and 
thrombogenesis.  
Due to its contrast flexibility and its high spatial resolution, MRI is a promising new 
technique for the characterization of inflammation in atherosclerosis. MRI of intraplaque 
macrophage activity using iron oxide particles is already under clinical investigation. 
Processes such as oxidative stress, proliferation, apoptosis and thrombogenesis were recently 
investigated by MRI. A fibrin marker for the diagnosis of thrombosis is under development 
for clinical trials. Newly designed gadolinium or iron oxide MR markers for molecular 
imaging have targeted integrins, immunoglobulins and selectins to characterize vessel wall 
inflammation and angiogenesis, but still have certain limitations for application in large-scale 
clinical trials 
In conclusion, molecular MRI of atherosclerosis is still in its infancy, and numerous targets 
and imaging strategies remain to be explored in close collaboration with molecular biologists. 
Information needs to be gathered from multiple modalities and experimental models to deal 
with the different facets of this complex chronic vascular disease. 
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Abbreviations and Acronyms 
 
CAM  = cell adhesion molecule (ICAM, VCAM, Selectins) 
CD44  = lymphocyte integrin, interaction with extracellular matrix (hyaluronan) 
CR3 or 4 = complement receptors for fragments 3 and 4 expressed on monocytes 
CRP  = C-reactive protein 
GP Ib-IX-V  = glycoprotein complex (=GP Ibα, GP Ibβ, GP IX and GP V), P selectin ligand 
ICAM  = intercellular adhesion molecule, LFA-1 ligand  
IFN-α  = interferon-alpha 
IL  = interleukin 
LFA-1  = lymphocyte function-associated antigen-1 (immunoglobulin) 
MCP-1  = monocyte chemoattractant protein-1 
MMP  = matrix metalloproteinase 
oxLDL  = oxidized low density lipoprotein 
PCAM  = platelet/endothelial cell adhesion molecule 
ROS  = reactive oxygen species 
sCD40L = soluble CD40 ligand 
TNF-α  = tumor necrosis factor-alpha 
VCAM  = vascular cell adhesion molecule, VLA-4 ligand 
VLA-4  = very late antigen-4, integrin 
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Tables and Figures 
 
 
Table 1: Targets of the main pathological processes assessed using specific MR markers and 
their associated MR protocols. 
 
Figure 1: Adhesion molecules and ligands involved in the initial phases of vascular 
inflammation (a), and cell responses in the vessel wall during inflammation and plaque 
formation (b). The initial inflammation cascade is shown with monocyte activation and 
secretion of TNF-α and IL1, followed by pathways involving monocytes, T-lymphocytes, 
endothelial cells and platelets (a). Endothelial cells are then activated and favor adherence of 
activated platelets and leukocytes (b). Smooth muscle cells are also activated and changed 
their phenotype. Plaque formation is also characterized by the presence of oxidized lipids, 
monocyte migration and homing of macrophages, with the final interrelationship between 
inflammation and thrombosis (b). 
 
Figure 2: Establishing a new standard for plaque characterization, from histology to MRI (ex 
vivo imaging) (ex-vivo MRI of a calcified lesion in a Watanabe rabbit). Top row: standard 
HES histology and Von Kossa staining for calcification. Bottom row: Ex-vivo multi-contrast 
MR images (T1 and T2 spin echo). No signal for calcified tissue is seen with either sequence 
(adapted from Chaabane et al., Magn Reson Mater Phy, 2000) 116. 
 
Figure 3: Dynamic contrast enhancement in the abdominal ApoE-/- mouse aorta with a 
macromolecular paramagnetic blood pool agent (from Chaabane et al., Magn Reson Mater 
Phy, 2004, with permission) 55
 
Figure 4: Inflammation imaging with iron oxide particles: susceptibility-induced signal loss in 
a cholesterol-fed rabbit after denudation and balloon angioplasty of the infra-renal abdominal 
aorta (adapted from M. Sigovan et al., submitted to Magn Reson Med). Top row: In vivo 
gradient echo imaging (pre- and post-contrast). Bottom row: Histology with Perls staining 
shows iron in blue at the shoulder of the lesion. Ex vivo multi-contrast images (from left to 
right: proton density, gradient echo and T2 spin echo) show signal loss at the same location. 
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Figure 5: Molecular imaging of inflammation in the mouse aortic sinus. Cardiac and 
respiratory gated MRI before and after injection of iron oxide nanoparticles targeted to the 
VCAM-1 adhesion molecule. The high specificity of the probe was obtained by grafting a 
peptide identified by phage display technique (from Nahrendorf et al., Circulation 2006, with 
permission) 91. 
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Table 1: Targets of the main pathological processes assessed using specific MR markers and 
their associated MR protocols. 
 
 
33,34,105Specific MR sequencesThrombusNo contrast agents (natural iron derivatives)Thrombogenesis
42,46,50
55,81
Clinical, dynamic T1, increased permeability and vascularity
T1, animals (rabbits, mice), increased permeability and vascularity
Non specific : permeability and leakage
Non specific : permeability and leakage
Gd Chelates
Blood pool agents (Gd liposomes, Gd macromolecules)
Inflammation
(Angiogenesis)
49,91
84
85,87
89
88
In vivo, ApoE mice, T2
Culture cells
Culture cells, mice (brain)
In vivo Rabbit aorta(fat diet), T1
In vivo Rabbit aorta(+drug), T1
Activated Endothelial cells
E selectin
E selectin
Integrins (αvβ3), 
Iron oxide particles (mimetic Ab VLA4+fluorochrome)
Iron oxide particles (CD62E Ab fragmant )
Functionnalized Gd complexes
Gd platforms (perfluorocarbon emulsion+ 
peptidomimetic vibronectiin antagonist)
Angiogenesis
106-108
109,110,122
Fibrin, T1 sequences, in vivo (rabbits, swine)
Fibrin (via Fibrin-Ab-avidin), T1 and 19F
Fibrin
Fibrin
Functionnalized Gd complexes (EP-, EPIX)
Gd platforms ((perfluorocarbon emulsion+ Biotin)Thrombogenesis
102
103,104
Cells expressing phosphatidylserine, mice, T2 
Cells expressing phosphatidylserine, T1/T2
Annexin V
Annexin V
Iron oxide particles (CLIO-Annexin v+Cy55)
Lipid-based Gd or Fe (+quantum dots)Apoptosis
101
56
In vitro, cultured SMC, 19F imaging
T1/T2 relaxivities (=f(B0))
SMC
Tissue Factor (via TF-Ab-avidin)
Gd platforms (perfluorocarbon emulsion+ Biotin)
Proliferation
95
81,82,96,97
99,121
100
In vitro LDL labelling
Gadofluorine, micelles or liposomes, rabbit aorta, T1
In vivo T1, mice
T1 upon enzyme activation, in vitro
Lipid distribution
Lipid distribution
MMP’s
Myeloperoxidase
LDL labelled (Gd chelates + Fluorochrome)
Lipophilic Gd chelates, HDL or Lipid-based Gd 
nanoparticles
Functionalized Gd chelate
Serotonin Gd chelate (SMART)
Oxydative stress
71
64,66,68,69,115
65,72-75
49,83,91
92
89,90
98,117
118
80,119,120
Ex-vivo T2* (SPIO)
In-vivo T2*(USPIO), rabbits
Clinical , T2* (aorta, carotids)
VCAM-1, T1/T2*ex-vivo, in-vivo (mice)
Selectins, T1, in-vivo (mice)
In vivo Rabbit aorta(fat diet), T1
Mice
Mice
Mice
Activated macrophages
Adhesion Molecules
Adhesion molecules
Integrins (αvβ3)
Macrophage scavanger receptor
Macrophages
Monocytes/Macrophages
Iron oxide particles (SPIO, USPIO)
Iron oxide particles (mimetic Ab VLA4+fluorochrome)
Gd platforms (biomimetic carboxymethyldextran-Gd)
Gd platforms (perfluorocarbon emulsion+ 
peptidomimetic vibronectin antagonist=RGD)
Gd micelles
Theranostics nanoparticles (multifunctional USPIO)
In vitro labeling (iron particles, Indium111)
Inflammation
ReferencesMR methodology, speciesTargetMR markersPathological
processes
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Figure 1: Adhesion molecules and ligands involved in the initial phases of vascular 
inflammation (a), and cell responses in the vessel wall during inflammation and plaque 
formation (b). The initial inflammation cascade is shown with monocyte activation and 
secretion of TNF-α and IL1, followed by pathways involving monocytes, T-lymphocytes, 
endothelial cells and platelets (a). Endothelial cells are then activated and favor adherence of 
activated platelets and leukocytes (b). Smooth muscle cells are also activated and changed 
their phenotype. Plaque formation is also characterized by the presence of oxidized lipids, 
monocyte migration and homing of macrophages, with the final interrelationship between 
inflammation and thrombosis (b). 
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Figure 2: Establishing a new standard for plaque characterization, from histology to MRI (ex 
vivo imaging) (ex-vivo MRI of a calcified lesion in a Watanabe rabbit). Top row: standard 
HES histology and Von Kossa staining for calcification. Bottom row: Ex-vivo multi-contrast 
MR images (T1 and T2 spin echo). No signal for calcified tissue is seen with either sequence 
(adapted from Chaabane et al., Magn Reson Mater Phy, 2000) 116. 
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 Figure 3: Dynamic contrast enhancement in the abdominal ApoE-/- mouse aorta with a 
macromolecular paramagnetic blood pool agent (from Chaabane et al., Magn Reson Mater 
Phy, 2004, with permission) 55
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 Figure 4: Inflammation imaging with iron oxide particles: susceptibility-induced signal loss in 
a cholesterol-fed rabbit after denudation and balloon angioplasty of the infra-renal abdominal 
aorta (adapted from M. Sigovan et al., submitted to Magn Reson Med). Top row: In vivo 
gradient echo imaging (pre- and post-contrast). Bottom row: Histology with Perls staining 
shows iron in blue at the shoulder of the lesion. Ex vivo multi-contrast images (from left to 
right: proton density, gradient echo and T2 spin echo) show signal loss at the same location. 
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Figure 5: Molecular imaging of inflammation in the mouse aortic sinus. Cardiac and 
respiratory gated MRI before and after injection of iron oxide nanoparticles targeted to the 
VCAM-1 adhesion molecule. The high specificity of the probe was obtained by grafting a 
peptide identified by phage display technique (from Nahrendorf et al., Circulation 2006, with 
permission) 91. 
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